Table 1 Mean (SD) values for markers of bone health among men and women with neurofibromatosis 1 (NF1); p values are given for the difference observed between the sexes
Analyte tested (reference range)MenWomenp Value
Serum calcium (2.13–2.63 mmol/l)2.42 (0.09)2.38 (0.10)0.075
Serum phosphate (0.77–1.50 mmol/l)1.03 (0.16)1.12 (0.18)0.034
Serum creatinine (0.5–1.0 mg/dl)0.8 (0.1)0.7 (0.1)<0.01
Serum alkaline phosphatase (34–104 U/I)67.1 (26.8)62.9 (18.4)0.465
Serum bone specific alkaline phosphatase (males: 8.0–16.8 μg/l; females: 7.5–15.7 μg/l)11.1 (4.4)10.2 (4.8)0.188
Serum leutenising hormone (males: 1.7–8.6 U/I; females: 1–9.5 U/I)6.3 (3.6)20.5 (19.2)<0.01
Serum follicle stimulating hormone (males: 1.5–12.4 U/I; females: 1.7–21.5 U/I)9.2 (6.4)31.9 (39.1)0.01
Serum oestradiol (males: 13.5–59.0 ng/l; females: 24.5–411 ng/l)30.7 (8.9)99.9 (119.5)0.03
Serum osteocalcin (3.1–13.7 μg/l)10.2 (5.6)9.6 (3.7)0.622
Serum parathyroid hormone (10–65 ng/l)62.4 (35.2)58.7 (22.2)0.836
Serum 25-hydroxy-vitamin D—winter (15.2–17.5 μg/l)*10.9 (5.0)14.0 (6.5)0.053
Serum 25-hydroxy-vitamin D—summer (22.0–27.0 μg/l)*19.5 (8.4)22.4 (7.6)0.205
Serum 1,25–di-hydroxy-vitamin D (22–46 ng/l)36.3 (13.0)38.5 (16.7)0.535
Serum bone TRAP5b (males: 1.5–4.7 U/l; females <50 years old: 1.1–3.9 U/l; females >50 years old: 1.4–4.2 U/l)3.5 (1.0)3.2 (0.9)0.197
Urine deoxypyridinoline cross-links (males: 2.3–5.4 nmol/mmol creatinine; females: 3.0–7.4 nmol/mmol creatinine)7.1 (4.4)7.5 (2.2)0.181
Urine calcium (3.0–5.0 mmol/24 h)4.6 (2.5)3.5 (2.1)0.059
Urine phosphate (10.0–32.0 mmol/24 h)24.2 (9.5)23.4 (10.2)0.536
Urine creatinine (0.8–1.5 g/24 h)1.4 (0.39)1.2 (0.42)<0.01
Creatinine clearance (100–155 ml/min)118 (41.6)100 (31.7)0.05
Total hip T score−1.5 (1.2)−1.1 (1.0)0.126
Lumbar spine T score−1.6 (1.4)−1.0 (1.3)0.088
  • *Values obtained from normal population sampled at time of blood collection for NF1 patients.